RedHill Biopharma (RDHL) Cash & Equivalents (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Cash & Equivalents data on file, last reported at $4.0 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $4.0 million, down 13.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.0 million (down 13.99% YoY), and the FY2025 annual result was $4.0 million, down 13.99% from the prior year.
• Cash & Equivalents eased to $4.0 million in Q4 2025 per RDHL's latest filing, from $4.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $51.8 million in Q2 2021 and troughed at $4.0 million in Q4 2025.
• A 5-year average of $20.1 million and a median of $20.0 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents surged 132.65% in 2021, then tumbled 72.11% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $29.5 million in 2021, then sank by 32.25% to $20.0 million in 2022, then plunged by 72.11% to $5.6 million in 2023, then declined by 17.09% to $4.6 million in 2024, then slipped by 13.99% to $4.0 million in 2025.
• Business Quant data shows RDHL's Cash & Equivalents at $4.0 million in Q4 2025, $4.6 million in Q2 2025, and $4.6 million in Q4 2024.